Moderna (MRNA) closed at $58.39 in the latest trading session, marking a -0.56% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.97%. Elsewhere, the Dow saw an ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

The rise in mRNA pharmaceuticals’ licensing agreement values suggests that this field will remain a major area for innovation ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

The Centers for Disease Control and Prevention (CDC) currently recommends that everyone aged 6 months and up get the Moderna or Pfizer COVID-19 vaccines. The Novavax vaccine is authorized by the U.S.

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

In the late 1980s, Ambros and Ruvkun were postdoctoral researchers in the laboratory of Robert Horvitz, who received the ...

Most investors unaware of the huge breakthroughs happening in biotech right now. But new technologies such as cancer-killing ...

The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. | The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. The committee has awarded two American biologists ...

Penn Engineers have discovered a simple and inexpensive means of directing lipid nanoparticles (LNPs), the revolutionary ...

The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health ...